Selective inhibitors of the integrin αvβ6

Abstract

The patent describes the production, purification, identification and characterisation of antibodies to the integrin αvβ6. The integrin αvβ6 has been implicated in several pathological conditions. Inhibition of the integrin is therefore of therapeutic value. Since the integrins are ubiquitous and involved in normal functioning of cells, selectivity is very important. The authors have shown that the antibody is selective for αvβ6. Use of this antibody in animal models is not shown.

• fibronectin
• inhibitor
• integrin alphavbeta6
• monoclonal antibody